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Defining protein interactions forms the basis for
discovery of biological pathways, disease mecha-
nisms, and opportunities for therapeutic intervention.
To harness the robust binding affinity and selectivity
of structured peptides for interactome discovery,
we engineered photoreactive stapled BH3 peptide
helices that covalently capture their physiologic
BCL-2 family targets. The crosslinking a helices
covalently trap both static and dynamic protein inter-
actors, and enable rapid identification of interaction
sites, providing a critical link between interactome
discovery and targeted drug design.
INTRODUCTION
Protein interactions mediate innumerable cellular activities in
health and disease. Like the teeth of a key that perfectly match
a lock, complementary protein shape is critical to the execution
of biological interactions. These contact points are embedded
within a complex protein structure that provides the infrastruc-
ture to maintain the essential bioactive fold. When the biological
activity of proteins is assigned to discrete subdomains, their
mode of action, menu of protein targets, and explicit sites of
target engagement are frequently unknown. Ideally, these evolu-
tionarily honed substructures could be used to capture and
thereby catalog their protein targets. However, out of context
from the whole protein, bioactive subdomains often unfold,
resulting in loss of biological shape, potency, and specificity.
From the surface of the cell to its inner nuclear core, a-helical
interactions govern such critical processes as infection (Weis-
senhorn et al., 1997), the immune response (Blum et al., 1993),
apoptosis (Sattler et al., 1997), and transcription (Kussie et al.,
1996). Importantly, the natural complexity of peptide a helices
enables them to discern among homologous targets. Whereas
some protein interaction sites are remarkably similar in topog-
raphy, helical peptides can function as high-fidelity ligands due
to the variability afforded by their amino acid composition.
Indeed, we have found that chemical stabilization of proapop-
totic BCL-2 family peptides yields reliable a-helical surrogates
that bind both stable and transient physiologic interactorsChemistry & Biology 17, 1325–133(Walensky et al., 2006), and even uncover novel sites of protein
interaction (Gavathiotis et al., 2008). To leverage the enormous
capacity of structured peptides to selectively bind and capture
their protein targets, we combined chemical restoration of
a-helical shape with installation of a covalent capture moiety
to generate photoreactive stabilized alpha-helices of BCL-2
domains (pSAHBs) for protein interaction analysis.
RESULTS
Development of pSAHBs: Synthesis, Binding Activity,
and Covalent Capture
pSAHBs are designed to incorporate through conservative
aromatic residue substitution a nonnatural amino acid bearing
a benzophenone moiety (4-benzoylphenylalanine, Bpa), which
covalently crosslinks to protein targets upon exposure to ultravi-
olet (UV) light (Dorman and Prestwich, 1994; Saghatelian et al.,
2004; Vodovozova, 2007) (Figure 1A). To restore a-helical struc-
ture to a synthetic peptide that incorporates Bpa, we further
install an i, i+4 pair of nonnatural amino acids bearing olefin
tethers that when subjected to ring closing metathesis yields
a hydrocarbon stapled peptide (Blackwell et al., 2001; Schaf-
meister et al., 2000). We generated a panel of pSAHBs modeled
after the BH3 death domain of the proapoptotic protein BAD
(Yang et al., 1995) to test our a-helical interaction covalent
capture strategy. Substitution of Bpa at each of the native
aromatic amino acid positions containedwithin BADBH3 yielded
BADpSAHBs1–4, three ofwhich (BADpSAHBs2–4) localizeBpa
to the BH3-binding interface (Figure 1B). Importantly, fluores-
cence polarization assays performed using FITC-derivatized
BAD pSAHBs and recombinant BCL-XLDC confirmed that Bpa
substitution did not disrupt target binding (Figure 1C).
FITC-BAD pSAHBs were incubated with BCL-XLDC at a ratio
of 1:1 and upon exposure to UV light, FITC-BAD pSAHB-2 and
to a lesser extent FITC-BAD pSAHB-4, which contain Bpa resi-
dues predicted to localize to the BAD BH3/BCL- XLDC binding
interface (PDB ID 2BZW), underwent crosslinking to BCL-XLDC
as detected by Coomassie stain and fluorescence scan (Fig-
ure 1D). Whereas the Bpa residue in FITC-BAD pSAHB-1 does
not localize to the helical binding interface and correspondingly
exhibited no crosslinking activity, FITC-BAD pSAHB-3, which
contains an F121Bpa substitution that does reside at the binding
interface, also showed no photoaffinity labeling. These data3, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1325
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Figure 1. Transformation of a Bioactive Peptide Domain into a Structurally Stable and Photoreactive a Helix
(A) Photoreactive stabilized a helix of BCL-2 domains (pSAHBs) for protein capture are generated by replacing native aromatic residues with 4-benzoyl-phenyl-
alanine (Bpa) followed by ring closing metathesis of olefinic nonnatural amino acids installed at i, i +4 positions.
(B) A panel of pSAHBs was modeled after the BH3 death domain of proapoptotic BAD.
(C) BAD pSAHBs retain high-affinity binding to antiapoptotic BCL-XLDC, as measured by fluorescence polarization assay. Error bars represent mean ± SD for
binding assays performed in at least triplicate.
(D) Select fluorescently labeled BAD pSAHBs crosslink to BCL-XLDC upon exposure to UV irradiation, as detected by Coomassie stain and fluorescence imaging.
(E) Time course for UV-dependent crosslinking of BAD pSAHB-2 to BCL-XLDC as monitored by Coomassie stain and fluorescence scan, and the corresponding
densitometry-based calculation of crosslinking yield using ImageJ software.
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Photoreactive Helices for Interaction Analysishighlight that even when target binding is uniformly preserved in
Bpa-substituted SAHBs (Figure 1C), generating a panel of
stapled peptides containing differentially localized photoreactive
moieties is advisable so that an optimal construct for protein
crosslinking can be identified. Kinetic analysis of a 1:1 peptide:
protein mixture of our most effective photoreactive a helix,
BAD pSAHB-2, demonstrated time-dependent production of1326 Chemistry & Biology 17, 1325–1333, December 22, 2010 ª2010crosslinked BCL-XLDC, with approximately 35% conversion by
2 hr of UV exposure (Figure 1E).
Binding Specificity of pSAHBs
To examine the specificity of covalent crosslinking, FITC-BAD
pSAHB-2 was first incubated with bovine serum albumin (BSA)
alone or with mixtures of BCL-XLDC containing increasingElsevier Ltd All rights reserved
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Figure 2. pSAHBs Selectively Capture their Physiologic Targets, Trapping Both Static and Dynamic Interactors
(A) The selectivity of BAD pSAHB covalent capture is highlighted by the absence of crosslinking to bovine serum albumin (BSA) and the inability of BSA to disrupt
FITC-BAD pSAHB-2/BCL-XLDC crosslinking.
(B) Biotinylated BAD pSAHB-2 was incubated with an equimolar mixture of homologous antiapoptotic proteins at the indicated ratios in the presence of UV light
for 1.5 hr. Western analysis of the isolated crosslinked proteins revealed high-fidelity capture of physiologic interactors BCL-XLDC, BCL-2DC, and BCL-wDC, but
not BFL1/A1DC, which lies outside the in vivo binding spectrum of the BAD protein. SA, streptavidin.
(C) A panel of pSAHBs was modeled after the BIM BH3 domain for comparative crosslinking studies with BAD pSAHBs.
(D) BAD and BIM pSAHBs covalently trap their distinct profile of antiapoptotic binding partners within U937 cellular extracts.
(E) In addition to capturing stable protein interactors, BIM pSAHBs 2–4 crosslink to proapoptotic BAX, a fleeting ‘‘hit and run’’ target of the BH3-only protein BIM.
See also Figure S1.
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Photoreactive Helices for Interaction Analysisamounts of BSA. In each case, FITC-BAD pSAHB-2 only cross-
linked to BCL-XLDC and the quantity of added BSA had no
impact on the yield of the FITC-BAD pSAHB-2/BCL-XLDC
adduct, which was equivalent across all conditions (Figure 2A).
To confirm that Bpa substitution itself did not account for the
absence of BSA binding, we conducted a fluorescence polariza-
tion binding assay comparing FITC-BAD SAHB and FITC-BAD
pSAHB-2 (see Figure S1A available online). We found that
wild-type and Bpa-substituted FITC-BAD SAHBs engaged
albumin with similarly low affinity, highlighting that covalent
capture of BCL-XLDC by BAD pSAHB is indeed selective and
that despite the abundance of BSA in the reaction mixture, no
off-target crosslinking is observed.
Having demonstrated that BAD pSAHB-2 was grossly selec-
tive for its protein target in vitro, we next investigated whether
the photoreactive stapled peptide could discriminate with high
fidelity among the variety of homologous antiapoptotic proteins
and crosslink only to its physiologic binding partners. Because
cells express variable levels of antiapoptotic proteins, potentiallyChemistry & Biology 17, 1325–133biasing crosslinking results based on relative protein abundance,
we first examined crosslinking fidelity by incubating increasing
amounts of biotinylatedBADpSAHB-2with an equimolarmixture
of recombinant BCL-2DC, BCL-XLDC, BCL-wDC, BFL-1/A1DC,
andMCL-1DNDC. FollowingUV irradiation, the reactionmixtures
were subjected to streptavidin (SA)-based affinity purification,
stringent washing to eliminate noncovalent binders, elution, elec-
trophoresis, and western analysis. Whereas exposure to BAD
pSAHB-2 caused dose-responsive photoaffinity labeling of
BCL-2DC, BCL-XLDC, and BCL-wDC, as reflected by
a 3.4 kDa molecular shift, no such effect was observed for
BFL-1/A1DC (Figure 2B). Because the truncated MCL-1DNDC
construct was not detected by available anti-MCL-1 antibodies,
we subjected the electrophoresed eluates to silver stain and
LC-MS/MS analysis, and confirmed that BAD pSAHB-2 likewise
did not crosslink to MCL-1DNDC (Figure S1B). Thus, pSAHBs
can be designed to retain high-affinity target binding and selec-
tively capture their physiologic interaction partners in the context
of an equimolar mixture of homologous protein targets.3, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1327
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Photoreactive Helices for Interaction AnalysispSAHBs Trap Static and Dynamic Protein Interactors
Wenext testedwhether pSAHBs could function as reliable surro-
gates of BH3 domain-containing proteins and discriminate
among homologous targets in a complex protein mixture.
Whereas proapoptotic BAD exhibits a selective antiapoptotic
binding profile, engaging BCL-XL but not MCL-1, proapoptotic
BIM broadly interacts with antiapoptotic proteins (Chen et al.,
2005). We incubated biotinylated BAD pSAHB-2 (Figure 1B) or
BIM pSAHB-3 (Figure 2C) with a cellular extract from U937
myeloid leukemia cells that overexpress both BCL-XL and
MCL-1 (Chen et al., 2007) in the presence or absence of UV
irradiation, followed by SA-based affinity purification, stringent
washing to eliminate noncovalent binders, elution, electropho-
resis, and western analysis. Whereas the nonirradiated samples
and vehicle-treated irradiated extracts showed no crosslinked
species, BAD pSAHB-2 crosslinked to endogenous BCL-XL
but not MCL-1, and BIM pSAHB-3 crosslinked to both proteins
(Figure 2D), mirroring the physiologic binding profile of the corre-
sponding BH3-only proteins.
Manycritical biological interactions are transient or are of insuf-
ficient affinity to withstand the experimental conditions required
to prepare cellular extracts or isolate complexes by affinity chro-
matography. In order to determine if pSAHBs could be applied to
capture fleeting a-helical interactions, we explored whether BIM
pSAHB could trap the defined ‘‘hit and run’’ interaction between
this directBH3activator andproapoptoticBAX (Gavathiotis et al.,
2008; Wei et al., 2000). Cellular extracts prepared from mouse
embryo fibroblasts were incubated with a panel of biotinylated
BIM pSAHBs (Figure 2C) in the presence of UV irradiation, fol-
lowed by isolation and analysis of BIM pSAHB-crosslinked
species. BIM pSAHB-1, the only construct containing a Bpa
moiety localized to the noninteracting surface of the BIM BH3
helix, exhibited little to no crosslinking activity. However, BIM
pSAHBs-3 and -4, and to a lesser extent BIM pSAHB-2, cova-
lently captured this otherwise fleeting target (Figure 2E). Thus,
by trapping transitory interactions in addition to static binding
events, pSAHBs can be used to probe the mechanisms of
dynamic BH3-mediated signal transduction events.
pSAHBs Localize the Site of Protein Interaction
Given the importance of pharmacologic targeting of protein
interactions in human disease, a rapid method for localizing
helix-target binding sites would be especially advantageous for
clinical translation. To explore the capacity of pSAHBs to effi-
ciently identify explicit sites of protein engagement, we sub-
jected a mixture of biotinylated BAD pSAHB-2 and BCL-XLDC
to UV exposure, followed by SA pull-down, SDS-PAGE electro-
phoresis, and excision of the crosslinked species for nano liquid
chromatography and tandemmass spectrometry (nano-LC-MS/
MS) analysis. MS/MS spectra were searched using the SE-
QUEST algorithm (Eng et al., 1994) against a database contain-
ing BCL-XLDC, trypsin, and common keratin contaminants. Bpa-
crosslinked tryptic fragments were identified by searching for the
variable modification corresponding to the mass of the tryptic
BCL-XLDC fragment plus the Bpa-containing pSAHB fragment,
UGR (482.22777 Da). To obtain an estimate for false-positive
detection rate (FDR), the reversed protein sequences were also
included in the database search (Elias and Gygi, 2010). The
subset of crosslinked peptides identified by the SEQUEST1328 Chemistry & Biology 17, 1325–1333, December 22, 2010 ª2010search were filtered such that the maximum FDR was 5%,
yielding a high confidence list of covalently modified sites, which
were plotted by frequency of occurrence (Figure 3A). Strikingly,
the Bpamoiety substituted at position Y110 of the BADBH3 helix
crosslinked to a discrete subset of amino acids that colocalized
within the canonical BH3-binding groove of BCL-XL. Indeed, the
single most frequently crosslinked BCL-XL residue, F105, repre-
sents the nearest neighbor to Y110 in the crystal structure of the
BAD BH3/BCL-XLDC complex (Figures 3B and 3C).
Having validated the capacity of a pSAHB to correctly localize
the ligand-target interface of a structurally defined interaction,
we next examined whether pSAHBs could be deployed to
pinpoint and characterize a structurally undefined binding inter-
face.We chose the full-length BCL-2 family antiapoptotic protein
BCL-w to pilot our methodology, as BCL-w is a potential target
of the BADBH3-mimetic drug ABT-263, which is currently in clin-
ical trials as an anticancer agent, yet a structural characterization
of BCL-w in complexwith its physiologic BADBH3 ligand has not
been reported. To obtain a pair of binding site coordinates for
computational docking analysis, recombinant BCL-w was incu-
bated with biotinylated BAD pSAHB-2 or BAD pSAHB-4 as a 1:1
mixture and subjected to UV irradiation, followed by SA pull-
down, electrophoresis, tryptic digestion of the excised cross-
linked species, and nano-LC-MS/MS analysis. Of note, we
created a tryptic site at the noninteracting face of BAD
pSAHB-4 by D123R mutagenesis in order to ensure that the
resultant Bpa-containing pSAHB-4 fragment was sufficiently
small for optimal MS/MS sequencing (i.e., SUK: 484.23218 Da;
SUKK: 611.34313 Da). As described above, Bpa-crosslinked
tryptic fragments were identified by searching for the variable
modifications corresponding to the masses of the tryptic BCL-
XLDC fragment plus the Bpa-containing pSAHB fragments,
yielding a filtered list of crosslinking sites for each BAD pSAHB,
plotted by frequency of occurrence per BCL-w residue (Figures
4A and 4B). As with BAD pSAHB-2/BCL-XLDC crosslinking, one
predominant amino acid site emerged with a frequency of occur-
rence that exceeded the average number of hits by more than
two standard deviations above the mean. This top scoring hit
for each pSAHB was then employed in computational docking
analysis (CNS within HADDOCK 2.0) (Brunger et al., 1998; Dom-
inguez et al., 2003) to calculate a model structure for the BAD
BH3/BCL-w interaction starting with the NMR structure of full-
length BCL-w (PDB ID 1O0L), the crystal structure of the BAD
BH3 helix (2BZW), and the active BAD pSAHB/BCL-w residue
pairs Y110/L63 and F125/R55.
The calculated model structures converged to position the
BAD BH3 helix at the canonical BH3-binding pocket of BCL-w
(Figure 4C; Figure S2), with the N to C terminus directionality of
the peptide disposed right to left and the interaction topography
notably similar to that of the BAD BH3/BCL-XLDC complex
previously determined by X-ray crystallography (PDB ID 2BZW)
(Figure 4D). The en face views of the complexes highlight the
homologous complementary electrostatic interactions at the
perimeter of the core hydrophobic binding interface, with
charged residues D119 and R115 of BAD BH3, respectively,
engaging R94 and E84 of BCL-w in an analogous manner to
the BAD BH3/BCL-XLDC interaction pairs D119/R139 and R115/
E129. The calculated orientation of core BAD BH3 residues
A106, Y110, L114, M117, F121, and F125 at the hydrophobicElsevier Ltd All rights reserved
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Figure 3. BAD pSAHB Precisely Localizes the Structurally Defined BAD BH3/BCL-XLDC Binding Site
(A) BAD pSAHB-2 was incubated with BCL-XLDC and the mixture subjected to UV irradiation (1.5 hr), SA pull-down, electrophoresis, excision of the crosslinked
protein, trypsin proteolysis, and LC-MS/MS analysis. The plot depicts the frequency of crosslinked sites identified across the BCL-XLDC polypeptide sequence.
Mapping of the crosslinked residues onto the BCL-XLDC structure revealed their striking colocalization within a circumscribed region of the canonical BH3-
binding pocket, with the frequency of occurrence reflected by the color scale. Green arrowheads, trypsin digestion sites.
(B) The predominant Bpa-crosslinked tryptic fragment contained a covalent modification of BCL-XLDC residue F105, as exemplified by the MS/MS spectrum
derived from collision-induced dissociation of the (M+4H)4+ precursor (0.37 parts per million mass accuracy).
(C) The most abundant crosslink, located between BAD pSAHB-2 Bpa110 and BCL-XLDC F105, precisely matches the structurally defined interaction between
BAD BH3 Y110 and BCL-XLDC F105 at the BH3-binding pocket of BCL-XLDC (PDB ID 2BZW).
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Photoreactive Helices for Interaction Analysisinterface of the BCL-w binding pocket are also remarkably
similar to the disposition of these same residues in the BAD
BH3/BCL-XLDC crystal structure, highlighting both the fidelity
and utility of the pSAHB approach. Thus, we establish an effi-Chemistry & Biology 17, 1325–133cient method for combining pSAHB-derived MS/MS site identi-
fication data with computational docking analysis to rapidly
localize and structurally characterize a peptide-helix/target
protein binding interface.3, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1329
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Figure 4. Application of pSAHBs to Localize
and Characterize a Structurally Undefined
Helix/Protein Interaction Site
(A and B) BAD pSAHB-2 (A) or BAD pSAHB-4 (B)
was incubated with full-length BCL-w and the
mixture subjected to UV irradiation, SA pull-
down, electrophoresis, excision of the crosslinked
protein, trypsin proteolysis, and LC-MS/MS anal-
ysis. The plots (left) and color scale (right) depict
the frequency of BCL-w crosslinked sites, which
map to distinct, circumscribed regions within the
canonical BH3-binding pocket of BCL-w (right).
(C) The top scoring hit for each pSAHB was
employed in computational docking analysis to
calculate a model structure for the BAD BH3/
BCL-w interaction. The BAD BH3 helix engages
the canonical BH3-binding pocket of BCL-w with
the N to C terminus of the peptide disposed right
to left. The en face view (top) demonstrates the
complementary electrostatic interactions of D119
and R115 of BAD BH3 with R94 and E84 of
BCL-w, respectively. A top view of the structure
(bottom) highlights the juxtaposition of crosslinked
positions Y110 and F125 (cyan) of the BAD BH3
helix with L63 and R55 of BCL-w, respectively,
along the core hydrophobic interface. The side
chains of hydrophobic, positively charged, nega-
tively charged, and hydrophilic residues are
colored yellow, blue, red and green, respectively.
To display an unobstructed view of the BH3-
binding site, the BCL-w C terminus is hidden in
the images.
(D) The interaction topography of the calculated
model structure of BAD BH3/BCL-w is notably
similar to that of the structurally defined BAD
BH3/BCL-XLDC complex (PDB ID 2BZW). The en
face view (top) demonstrates the homologous
BAD BH3/BCL-XLDC electrostatic interaction
pairs D119/R139 and R115/E129, whereas the
core BAD BH3 residues A106, Y110, L114, M117,
F121, and F125 of the hydrophobic interface
(bottom) are remarkably similar in disposition to
these same residues in the calculatedmodel struc-
ture of BAD BH3/BCL-w.
See also Figure S2.
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Photoreactive Helices for Interaction AnalysisDISCUSSION
Here, we provide the blueprints for developing a novel, versatile,
and potentially expansive reagent set for protein capture based
on the generation of photoreactive stapled peptide helices. By1330 Chemistry & Biology 17, 1325–1333, December 22, 2010 ª2010 Elsevier Ltd All rights reharnessing the native and complex
topography of a critical protein interaction
motif of the BCL-2 family, pSAHBs serve
as high-fidelity research tools that effi-
ciently, selectively, and irreversibly cross-
link both static and dynamic protein
targets for proteomic and mechanistic
analyses. In addition, the compounds
can be applied to locate protein interac-
tion sites, which may serve as templates
for therapeutic targeting. This capacity
to rapidly and accurately map bindinginterfaces using a combinedMS/MS and computational docking
strategy provides an alternative and complementary approach
to bridging the gap between discovering protein interactions
and defining biologically relevant interfaces using definitive
structural methods, which can often take years to accomplish.served
Chemistry & Biology
Photoreactive Helices for Interaction AnalysisA unique and compelling feature of this approach is the ability to
conduct rigorous validation studies for the identified targets and
their sites of interaction. Because stapled peptides can pene-
trate intact cells and access their intracellular targets, the very
reagents used for covalent capture can be applied to vet and
potentially drug the interactions in cellular and in vivo studies
(Bernal et al., 2007; Gavathiotis et al., 2008; Stewart et al.,
2010; Walensky et al., 2004, 2006). Thus, the development and
application of photoreactive stapled peptide helices represents
a potentially powerful approach to identifying, distinguishing,
and modulating protein targets relevant to homeostatic and
pathologic cellular processes.
SIGNIFICANCE
We combined peptide a helix stabilization, photoaffinity
labeling, proteomic analysis, and structure calculation to
generate a new strategy for both (1) expanding our grasp
of the static and dynamic a-helical interactome of the
BCL-2 family and (2) localizing and targeting BH3 a helix/
protein interaction sites. Whereas hydrocarbon stapling
transforms unfolded peptides intoa helices that recapitulate
their native biological activities, the installation of a photo-
reactive moiety effectively adapts them for high-fidelity
covalent capture of the broad range of physiologic interac-
tors within complex protein mixtures. To date, stapled
peptides have been applied to develop a new therapeutic
strategy for targeting intracellular protein interactions
(Bernal et al., 2007; Moellering et al., 2009; Walensky et al.,
2004; Zhang et al., 2008), uncover an unanticipated function
for a death protein in metabolism (Danial et al., 2008), struc-
turally define the elusive activation site on an essential
executioner protein of the cell death pathway (Gavathiotis
et al., 2008), and identify a natural a-helical peptide that
can function as an exclusive inhibitor of a formidable antia-
poptotic protein linked to cancer chemoresistance (Stewart
et al., 2010). We believe that the development of photoreac-
tive stapled peptides will extend the potential for discovery
of novel and unforeseen protein interactions and how they
impact health and disease. Indeed, the stapled peptide
constructs used to capture protein targets can be applied
to interrogate them in a cellular context and provide the
templates for developing novel therapeutics.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptide synthesis, olefin metathesis, amino terminal derivatization (e.g., FITC-
bAla, biotin), reverse-phase HPLC purification, and microanalysis were per-
formed as previously described (Bird et al., 2008).
Protein Production
Glutathione S-transferase fusion proteins of BCL-XLDC, BCL-2DC, BCL-wDC,
BFL1/A1DC, and MCL-1DNDC were expressed in Escherichia coli BL21 using
pGEX2T (Pharmacia Biotech) and purified by affinity chromatography with
glutathione-Sepharose beads (GE Health Care), as described (Stewart et al.,
2010). Tagless protein was obtained by overnight on-bead cleavage of the
GST tag using 50 U thrombin protease (GE Life Sciences) in PBS buffer at
room temperature followed by size-exclusion chromatography. A histidine-
tagged full-length BCL-w construct (Qiagen) for binding site analysis was ex-
pressed in BL21 competent cells and purified by Ni-NTA chromatography, fol-Chemistry & Biology 17, 1325–133lowed by size exclusion chromatography. Protein concentrations were deter-
mined using the Bradford assay (Biorad).
Fluorescence Polarization Binding Assay
Fluoresceinated BAD BH3 peptides (50 nM) were incubated with BCL-XLDC
protein at the indicated concentrations in binding buffer (150 mM NaCl,
50 mM Tris-HCl [pH 8.0]) at room temperature. Binding activity was measured
at equilibrium (20min) by fluorescence polarization using a SpectraMaxmicro-
plate reader (Molecular Devices). EC50 values were calculated by nonlinear
regression analysis of dose-response curves using Prism software 5.0
(GraphPad).
Photoaffinity Labeling of Recombinant Proteins
Mixtures of recombinant protein and pSAHB at the indicated concentrations
were vortexed, incubated for 20 min in the dark, and then irradiated
(365 nm, Spectroline Handheld UV Lamp Model En280L, Spectronics Corp.)
for 1.5 hr at room temperature. For FITC-pSAHB crosslinking experiments,
the mixtures were diluted with 4 3 LDS load buffer (Invitrogen), electrophor-
esed using 12%Bis-Tris gels (Invitrogen), and analyzed by Coomassie staining
(SimplyBlue Safestain, Invitrogen) and fluorescence imaging (Gel Doc XR
Molecular Imager and Quantity One software, Bio-Rad). Binding specificity
experiments using bovine serum albumin (BSA) were conducted as above
except that BSA was added at the indicated concentrations prior to addition
of BAD pSAHB. For biotinylated-pSAHB crosslinking, unreacted peptide
was removed from the irradiated samples by overnight dialysis at 4C in Buffer
B (200 mM NaCl, 50 mM Tris [pH 7.4]) using 6–8 kD molecular weight cutoff
D-Tube dialyzers (EMD Biosciences). After addition of SDS to a final concen-
tration of 0.2%, biotin capture was achieved by incubation with high-capacity
streptavidin agarose (50 ml 50% slurry/reaction) for 2 hr at room temperature.
The streptavidin beads were successively washed at room temperature in
1% SDS in PBS, 1 M NaCl in PBS, and then 10% ethanol in PBS for 3 3
10 min each. Biotinylated proteins were eluted by boiling for 30 min in
a 10% SDS solution (Promega) containing D-biotin (10 mg/ml), electrophor-
esed using 4%–12% gradient Bis-Tris gels (Invitrogen), and then subjected
to western analysis for BCL-2 family targets (Santa Cruz Biotechnology:
BCL-XL, sc-634; BCL-2, sc-492; BCL-w, sc-6172; BAX, sc-493; Abcam:
BFL1/A1, ab75887). Electrophoresed samples were also subjected to silver
staining, band excision, in-gel digestion, and LC-MS/MS-based antiapoptotic
protein identification, as described below.
Photoaffinity Labeling of Cellular Lysates
Cellular lysates were generated from U937 cells or mouse embryo fibroblasts
(MEFs) grown under standard culture conditions (U937: RPMI 1640 [Invitro-
gen] supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, 50mMHEPES, and 50 mM b-mer-
captoethanol; MEF: DMEM [Invitrogen] supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate,
50 mM b-mercaptoethanol, and 2 mM L-glutamine). Cells were treated with
ice cold Buffer A (50 mM Tris [pH 7.4], 150 mM NaCl, 1% CHAPS, 1 mM
EDTA, 1.5 mM MgCl2, EDTA-free complete protease inhibitor cocktail
[Roche]), and the supernatant isolated by centrifugation. The supernatant
was maintained at 4C and precleared for 2 hr in high-capacity streptavidin
agarose (Pierce) that was pre-equilibrated in lysis buffer (35 ml 50% slurry/
mg lysate). Precleared lysates were diluted to a final concentration of
4.5 mg/ml with cold lysis buffer and incubated with biotinylated pSAHB
(10 mM for U937 experiments [500 ml total volume], and 100 mM for MEF
experiments [200 ml total volume]), and then irradiated, subjected to streptavi-
din-based isolation (as described above), and the electrophoresed pSAHB-
crosslinked proteins analyzed by anti-BCL-XL, anti-MCL-1, and anti-BAX
western blotting (sc-634, sc-819, and N20 antibodies, respectively; Santa
Cruz Biotechnology).
pSAHB Interaction Site Analysis
For interaction site analysis, pSAHBs (20 mM) were mixed with BCL-XLDC or
BCL-w (20 mM) in PBS for 20 min followed by irradiation or incubation in the
dark (i.e., nonirradiated control) for 1.5 hr. Reaction samples were subjected
to gel electrophoresis and then control and crosslinked bands were excised
and destained at 37C in a 50 mM ammonium bicarbonate aqueous solution3, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1331
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cycles of acetonitrile incubation (5 min), solvent removal, and elimination of
residual solvent by speedvac (Thermo Scientific). Gel slices were rehydrated
in reducing buffer (25 mM dithiothreitol in 100 mM ammonium bicarbonate)
and incubated at 55C for 30 min. Samples were then cooled to room temper-
ature, and partially dehydrated by incubation with acetonitrile for 5 min. Aceto-
nitrile was removed and replaced with alkylation buffer (10 mM iodoacetamide
in 50 mM ammonium bicarbonate), and samples were incubated at room
temperature in the dark for 1 hr. After removal of alkylation buffer, gel slices
were washed three times with 100 mM ammonium bicarbonate for 15 min
in the dark, dehydrated with acetonitrile, and residual solution eliminated by
speedvac. For in-gel digestion, gel slices were rehydrated with sufficient
digestion buffer (12.5 ng/ml sequencing grade modified-trypsin [Promega] in
50mMammonium bicarbonate) to completely cover each slice, and incubated
for 16 hr at 37Covernight. After removal of the digestion buffer, gel slices were
washed twice for 15minwith 5% formic acid in 50%acetonitrile. Digestion and
wash solutions were then combined and evaporated by speedvac, and the
samples resuspended in 40 ml of 5% formic acid in 5% acetonitrile and
desalted using C18 STAGE tips (Rappsilber et al., 2007). Desalted samples
were subjected to LC-MS/MS in an LTQ Orbitrap XL hybrid mass spectrom-
eter (ThermoFisher, San Jose, CA). The instrument was operated in data-
dependent mode using a setup similar to that described previously (Haas
et al., 2006). MS/MS spectra were searched using the SEQUEST algorithm
(Eng et al., 1994) against a partially tryptic database containing BCL-XLDC
or BCL-w, trypsin, and common keratin contaminants. Bpa-crosslinked tryptic
fragments were identified by searching for the variable modification corre-
sponding to the mass of the tryptic BCL-XLDC or BCL-w fragment plus the
Bpa-containing pSAHB fragment. The reversed protein sequences were also
included in the database to generate an estimate of false-positive detection
rate (FDR). The subset of crosslinked peptides identified by the SEQUEST
search were filtered based on tryptic state, charge state, mass accuracy,
peptide length, and number of correct matches per protein, such that the
maximum FDR was 5%. SEQUEST results containing more than one instance
of photoaffinity labeling were excluded from the data set, as the crosslinking
stoichiometry was assumed to be 1:1. The resultant list of covalently modified
sites was plotted by frequency of occurrence across the polypeptide
sequence of BCL-XLDC or BCL-w. To depict the crosslinking ‘‘hot spots’’ on
the protein structure, a red to blue color scale was assigned by converting
crosslinking frequencies to percent of maximum occurrence and then colored
by groups of ten percentiles.
Structure Calculation
Model structures of BAD BH3/BCL-w complexes were calculated using crys-
tallography and NMR system solve (CNS) (Brunger et al., 1998) within
HADDOCK 2.0 (Dominguez et al., 2003). Starting structures were (1) the
NMR structure of BCL-w (PDB ID 1O0L) with the C-terminal helix displaced
from the BH3 pocket and energy minimized using the molecular dynamics
software GROMOS (Van Der Spoel et al., 2005) and (2) the X-ray structure of
the BAD BH3 helix derived from the BAD BH3/BCL-XLDC complex (PDB ID
2BZW). The docking calculations generated models of the BAD BH3/BCL-w
complex based on interaction restraints derived from the crosslinking experi-
ments between BAD pSAHBs and BCL-w, and electrostatic and van derWaals
interactions were optimized based on a combination of molecular dynamics
and energy minimization protocols. Interacting residues designated by the
crosslinking experiments were more than 50% solvent accessible as deter-
mined by NACCESS (Hubbard and Thornton, 1993). The two sets of residues
based on the top scoring hits from MS/MS analysis were (1) BAD BH3 Y110
and BCL-w L63 and (2) BAD BH3 F125 and BCL-w R55. The force constants
for the restraints were set to 10 kcal mol1 A˚2 for the rigid-body docking stage
and then set to a final value of 50 kcal mol1 A˚2 during the semiflexible simu-
lated annealing stage. The restraints were set to be satisfied as soon as any
one of the distances entering the sum average ([S1/r6]1/6), over all individual
pairwise combinations, were within the defined cutoff distance of 2 A˚. The
docking calculations were performed with standard HADDOCK protocols
(Arnesano et al., 2004). Initially, 2000 orientations/structures of the complex
were generated by rigid-body docking energy minimization of the individual
structures. At this stage, structures were docked based on the restraints,
van der Waals, and electrostatic energy terms. The 100 better-scored struc-1332 Chemistry & Biology 17, 1325–1333, December 22, 2010 ª2010tures were semiflexibly refined in torsion angle space and then refined in
explicit water (Linge et al., 2003). Final structures were calculated following
water refinement and energy minimization. During the simulated annealing
and water refinement, all BAD BH3 amino acids (side chains and backbone)
were allowed to move to optimize the interface packing. In addition, at this
stage, specific segments of the BCL-w structure that comprise the BH3
pocket, including a2 (aa 40–57), a3 (aa 58–69), a4 (aa 70–89), a5 (aa 90–113),
and a9 (aa 151–172) were fully flexible (side chains and backbone). The 20
lowest-scored structures from the water refinement step were clustered
into one group using pairwise backbone root mean square deviation (rmsd)
of 3 A˚. The final structure ensemble was evaluated for chirality and
stereochemistry with the programs WHATCHECK (Hooft et al., 1996) and
PROCHECK_NMR (Laskowski et al., 1996), and then displayed and analyzed
using PYMOL (DeLano, 2002).SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.chembiol.2010.09.015.
ACKNOWLEDGMENTS
We thank E. Smith for figure design and editorial assistance. This work was
supported by NIH grant 5P01CA92625, 1R01GM090299, and a Stand Up to
Cancer Innovative Research Grant to L.D.W., and a National Sciences and
Engineering Research Council of Canada postgraduate scholarship to
C.R.B. L.D.W. is a consultant and scientific advisory board member for Aileron
Therapeutics.
Received: December 29, 2009
Revised: August 10, 2010
Accepted: September 27, 2010
Published: December 21, 2010
REFERENCES
Arnesano, F., Banci, L., Bertini, I., and Bonvin, A.M. (2004). A docking
approach to the study of copper trafficking proteins; interaction between
metallochaperones and soluble domains of copper ATPases. Structure 12,
669–676.
Bernal, F., Tyler, A.F., Korsmeyer, S.J., Walensky, L.D., and Verdine, G.L.
(2007). Reactivation of the p53 tumor suppressor pathway by a stapled p53
peptide. J. Am. Chem. Soc. 129, 2456–2457.
Bird, G.H., Bernal, F., Pitter, K., and Walensky, L.D. (2008). Chapter 22
synthesis and biophysical characterization of stabilized alpha-helices of
BCL-2 domains. Methods Enzymol. 446, 369–386.
Blackwell, H.E., Sadowsky, J.D., Howard, R.J., Sampson, J.N., Chao, J.A.,
Steinmetz, W.E., O’Leary, D.J., and Grubbs, R.H. (2001). Ring-closing metath-
esis of olefinic peptides: design, synthesis, and structural characterization of
macrocyclic helical peptides. J. Org. Chem. 66, 5291–5302.
Blum, J.H., Stevens, T.L., and DeFranco, A.L. (1993). Role of the mu immuno-
globulin heavy chain transmembrane and cytoplasmic domains in B cell
antigen receptor expression and signal transduction. J. Biol. Chem. 268,
27236–27245.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: a new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.
Chen, L., Willis, S.N., Wei, A., Smith, B.J., Fletcher, J.I., Hinds, M.G., Colman,
P.M., Day, C.L., Adams, J.M., and Huang, D.C. (2005). Differential targeting of
prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary
apoptotic function. Mol. Cell 17, 393–403.
Chen, S., Dai, Y., Harada, H., Dent, P., and Grant, S. (2007). Mcl-1 down-regu-
lation potentiates ABT-737 lethality by cooperatively inducing Bak activation
and Bax translocation. Cancer Res. 67, 782–791.Elsevier Ltd All rights reserved
Chemistry & Biology
Photoreactive Helices for Interaction AnalysisDanial, N.N.,Walensky, L.D., Zhang, C.Y., Choi, C.S., Fisher, J.K., Molina, A.J.,
Datta, S.R., Pitter, K.L., Bird, G.H., Wikstrom, J.D., et al. (2008). Dual role of
proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14,
144–153.
DeLano, W.L. (2002). The PyMOL Molecular Graphics System, http://www.
pymol.org. edn (San Carlos, DeLano Scientific).
Dominguez, C., Boelens, R., and Bonvin, A.M. (2003). HADDOCK: a protein-
protein docking approach based on biochemical or biophysical information.
J. Am. Chem. Soc. 125, 1731–1737.
Dorman, G., and Prestwich, G.D. (1994). Benzophenone photophores in
biochemistry. Biochemistry 33, 5661–5673.
Elias, J.E., and Gygi, S.P. (2010). Target-decoy search strategy for mass spec-
trometry-based proteomics. Methods Mol. Biol. 604, 55–71.
Eng, J.K., McCormack, A.L., and Yates, J.R. (1994). An approach to correlate
tandemmass spectral data of peptides with amino acid sequences in a protein
database. J. Am. Soc. Mass Spectrom. 5, 976–989.
Gavathiotis, E., Suzuki, M., Davis, M.L., Pitter, K., Bird, G.H., Katz, S.G., Tu,
H.C., Kim, H., Cheng, E.H., Tjandra, N., et al. (2008). BAX activation is initiated
at a novel interaction site. Nature 455, 1076–1081.
Haas, W., Faherty, B.K., Gerber, S.A., Elias, J.E., Beausoleil, S.A., Bakalarski,
C.E., Li, X., Villen, J., and Gygi, S.P. (2006). Optimization and use of peptide
mass measurement accuracy in shotgun proteomics. Mol. Cell. Proteomics
5, 1326–1337.
Hooft, R.W., Vriend, G., Sander, C., and Abola, E.E. (1996). Errors in protein
structures. Nature 381, 272.
Hubbard, S.J., and Thornton, J.M. (1993). NACCESS (London: University
College).
Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J.,
and Pavletich, N.P. (1996). Structure of the MDM2 oncoprotein bound to the
p53 tumor suppressor transactivation domain. Science 274, 948–953.
Laskowski, R.A., Rullmannn, J.A., MacArthur, M.W., Kaptein, R., and
Thornton, J.M. (1996). AQUA and PROCHECK-NMR: programs for checking
the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477–486.
Linge, J.P., Habeck, M., Rieping, W., and Nilges, M. (2003). ARIA: automated
NOE assignment and NMR structure calculation. Bioinformatics 19, 315–316.
Moellering, R.E., Cornejo, M., Davis, T.N., Del Bianco, C., Aster, J.C.,
Blacklow, S.C., Kung, A.L., Gilliland, D.G., Verdine, G.L., and Bradner, J.E.
(2009). Direct inhibition of the NOTCH transcription factor complex. Nature
462, 182–188.Chemistry & Biology 17, 1325–133Rappsilber, J., Mann, M., and Ishihama, Y. (2007). Protocol for micro-purifica-
tion, enrichment, pre-fractionation and storage of peptides for proteomics
using StageTips. Nat. Protoc. 2, 1896–1906.
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and Cravatt, B.F.
(2004). Activity-based probes for the proteomic profiling of metalloproteases.
Proc. Natl. Acad. Sci. USA 101, 10000–10005.
Sattler, M., Liang, H., Nettesheim, D., Meadows, R.P., Harlan, J.E., Eberstadt,
M., Yoon, H.S., Shuker, S.B., Chang, B.S., Minn, A.J., et al. (1997). Structure of
Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis.
Science 275, 983–986.
Schafmeister, C., Po, J., and Verdine, G. (2000). An all-hydrocarbon cross-link-
ing system for enhancing the helicity andmetabolic stability of peptides. J. Am.
Chem. Soc. 122, 5891–5892.
Stewart, M.L., Fire, E., Keating, A.E., and Walensky, L.D. (2010). The MCL-1
BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat.
Chem. Biol 6, 595–601.
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A.E., and
Berendsen, H.J. (2005). GROMACS: fast, flexible, and free. J. Comput.
Chem. 26, 1701–1718.
Vodovozova, E.L. (2007). Photoaffinity labeling and its application in structural
biology. Biochemistry (Mosc.) 72, 1–20.
Walensky, L.D., Kung, A.L., Escher, I., Malia, T.J., Barbuto, S., Wright, R.D.,
Wagner, G., Verdine, G.L., and Korsmeyer, S.J. (2004). Activation of apoptosis
in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470.
Walensky, L.D., Pitter, K., Morash, J., Oh, K.J., Barbuto, S., Fisher, J., Smith,
E., Verdine, G.L., and Korsmeyer, S.J. (2006). A stapled BID BH3 helix directly
binds and activates BAX. Mol. Cell 24, 199–210.
Wei, M.C., Lindsten, T., Mootha, V.K., Weiler, S., Gross, A., Ashiya, M.,
Thompson, C.B., and Korsmeyer, S.J. (2000). tBID, a membrane-targeted
death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14,
2060–2071.
Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley, D.C.
(1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387,
426–430.
Yang, E., Zha, J., Jockel, J., Boise, L.H., Thompson, C.B., and Korsmeyer, S.J.
(1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and
promotes cell death. Cell 80, 285–291.
Zhang, H., Zhao, Q., Bhattacharya, S., Waheed, A.A., Tong, X., Hong, A.,
Heck, S., Curreli, F., Goger, M., Cowburn, D., et al. (2008). A cell-penetrating
helical peptide as a potential HIV-1 inhibitor. J. Mol. Biol. 378, 565–580.3, December 22, 2010 ª2010 Elsevier Ltd All rights reserved 1333
